Edition:
United Kingdom

Genscript Biotech Corp (1548.HK)

1548.HK on Hong Kong Stock

24.95HKD
23 Feb 2018
Change (% chg)

HK$1.05 (+4.39%)
Prev Close
HK$23.90
Open
HK$24.70
Day's High
HK$25.45
Day's Low
HK$24.30
Volume
16,403,300
Avg. Vol
20,955,850
52-wk High
HK$34.00
52-wk Low
HK$3.15

Latest Key Developments (Source: Significant Developments)

Genscript Biotech Announces Acquisition Of Customarray
Tuesday, 26 Dec 2017 

Dec 27 (Reuters) - Genscript Biotech Corp <1548.HK>::ANNOUNCES ACQUISITION OF 100% OF ENTIRE ISSUED SHARES OF CUSTOMARRAY, INC..  Full Article

Genscript Biotech Says US, Ireland Units ‍& Janssen Biotech Enter Collaboration & License Agreement ​
Thursday, 21 Dec 2017 

Dec 22 (Reuters) - Genscript Biotech Corp <1548.HK>::US, IRELAND UNITS ‍& JANSSEN BIOTECH ENTER COLLABORATION & LICENSE AGREEMENT TO DEVELOP MULTIPLE MYELOMA PRODUCTS ​.‍ACCORDING TO DEAL , JANSSEN SHALL UPFRONT PAYMENTS OF US$350 MILLION TO UNIT FOR RIGHTS GRANTED​.  Full Article

Janssen Enters Collaboration And License Agreement With China's Legend Biotech To Develop CAR-T Cancer Therapy
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Johnson & Johnson ::JANSSEN ENTERS WORLDWIDE COLLABORATION AND LICENSE AGREEMENT WITH CHINESE COMPANY LEGEND BIOTECH TO DEVELOP INVESTIGATIONAL CAR-T ANTI-CANCER THERAPY.JANSSEN BIOTECH - J&J REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE GUIDANCE OF $7.25 - $7.30.FY2017 EARNINGS PER SHARE VIEW $7.28 -- THOMSON REUTERS I/B/E/S.JANSSEN - ENTERED INTO WORLDWIDE COLLABORATION, LICENSE DEAL WITH UNITS OF GENSCRIPT BIOTECH CORPORATION.JANSSEN SAYS UNDER AGREEMENT, IT WILL MAKE AN UPFRONT PAYMENT OF $350 MILLION THAT WILL BE RECORDED IN Q4.JANSSEN SAYS COS ENTERED INTO A 50/50% COST-SHARING/PROFIT-SPLIT ARRANGEMENT, EXCEPT IN GREATER CHINA.JANSSEN SAYS IN GREATER CHINA, JANSSEN AND LEGEND HAVE A 30/70 PERCENT COST-SHARING/PROFIT-SPLIT ARRANGEMENT.  Full Article

Genscript Biotech Unit's‍ Application For Investigational New Drug Accepted By China FDA
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Genscript Biotech Corp <1548.HK>::‍APPLICATION FOR INVESTIGATIONAL NEW DRUG BY UNIT ACCEPTED BY CHINA FDA.  Full Article

Genscript Biotech Corp updates on shareholding changes in GS Corp ​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Genscript Biotech Corp <1548.HK>::‍INFORMED THAT ADDITIONAL 50 MILLION SHARES & 25 MILLION SHARES OF GS CORP WERE TRANSFERRED TO ZHANG TRUST & WANG TRUST, RESPECTIVELY​.  Full Article

Genscript Biotech Corp says ‍Kanglitai informed by CFDA of approval on clinical trial
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Genscript Biotech Corp <1548.HK>:Kanglitai informed by CFDA of approval on clinical trial; approved to commence clinical studies of KLT-1101​.  Full Article

Genscript Biotech Corp updates on transfer of shares of GS Corp
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Genscript Biotech Corp <1548.HK>:Informed by GS Corp that 5 million shares & 2.5 million shares of GS Corp were transffered to Zhang Trust and Wang Trust respectively.  Full Article

Genscript Biotech updates on development of new drug​
Monday, 29 May 2017 

May 29 (Reuters) - Genscript Biotech Corp <1548.HK>:‍application for clinical trial on KLT-1101 was accepted by China food and drug administration on 4 May 2017.​.  Full Article

Genscript Biotech issues profit alert<1548.HK>
Friday, 15 Jul 2016 

Genscript Biotech Corp <1548.HK>: Bio-positive profit alert . The group is expecting to record a significant increase in the net profit for the six months ended 30 June 2016 .Says expected increase is mainly attributable to the increase in the number of purchase orders placed by customers.  Full Article

GenScript Biotech updates on investment agreement<1548.HK>
Tuesday, 21 Jun 2016 

Genscript Biotech Corp <1548.HK>: Bio-discloseable transaction in relation to the investment agreement <1548.HK> . GenScript HK and Zhenjiang Committee entered into the investment agreement .  Full Article

BRIEF-Genscript Biotech Says ‍Huang Zuie-Chin Resigns As Non-Executive Director​

* ‍HUANG ZUIE-CHIN RESIGNED AS A NON-EXECUTIVE DIRECTOR​ Source text for Eikon: Further company coverage: